Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.4K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.4K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

92.8K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
92.8K
Human Genetics01:28

Human Genetics

2.0K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Social determinants of vulnerability to nitrogen oxide- and sulfur dioxide-related bone damage among postmenopausal women in the United States.

Frontiers in public health·2026
Same author

Integrating a Non-Communicable Disease Care Cascade within Ghana's Community-Based Health Planning and Services (CHPS) Program: the COMBINE Pilot Implementation Trial.

medRxiv : the preprint server for health sciences·2026
Same author

The Role of the Pediatric Pharmacist in Precision Medicine and Clinical Pharmacogenomics for Children.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same author

Altered neurodevelopmental trajectories of brain structure in Tourette syndrome and Chronic Tic Disorders.

medRxiv : the preprint server for health sciences·2026
Same author

Chronic kidney disease, complex conditions, and advancing therapeutics: new hope and challenges.

Lancet (London, England)·2026
Same author

MarkerMatch: a proximity-based probe-matching algorithm for joint analysis of copy-number variants from different genotyping arrays.

Bioinformatics (Oxford, England)·2026

Related Experiment Video

Updated: May 7, 2026

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:43

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

245

Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial.

Kathryn V Blake1, Lindsay J Hines2,3, Michelle Liu4

  • 1Center for Pharmacogenomics and Translational Research, Nemours Children's Health, Jacksonville, Florida.

JAMA Network Open
|May 6, 2026
PubMed
Summary

Pharmacogenetic-guided prescribing of selective serotonin reuptake inhibitors (SSRIs) did not improve depression symptoms at 3 months. However, it was associated with higher depression remission rates at 6 months, suggesting a potential longer-term benefit.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

747
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.8K

Related Experiment Videos

Last Updated: May 7, 2026

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:43

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

245
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

747
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.8K

Area of Science:

  • Pharmacogenomics and Precision Medicine
  • Psychiatry and Mental Health Research
  • Clinical Trial Design and Execution

Background:

  • The effectiveness of using pharmacogenetics to guide selective serotonin reuptake inhibitor (SSRI) prescribing for depression is not well-established.
  • Genetic variations significantly influence SSRI pharmacokinetics, highlighting the potential for personalized prescribing strategies.
  • Previous research has not definitively shown whether genotype-guided SSRI use improves treatment outcomes in depression.

Purpose of the Study:

  • To evaluate if pharmacogenetic-guided SSRI prescribing enhances treatment response in patients diagnosed with depression.
  • To compare depression symptom improvement and remission rates between genotype-guided and usual care treatment arms.
  • To assess the impact of pharmacogenetic guidance on SSRI adverse effects.

Main Methods:

  • A pragmatic randomized clinical trial (ADOPT PGx Depression) involving 1460 patients (aged 8+) with depression.
  • Participants were randomized to either genotype-guided SSRI prescribing based on actionable drug metabolism phenotypes or usual care.
  • Primary outcome: change in Patient-Reported Outcomes Measurement Information System (PROMIS) depression T scores at 3 months; Secondary outcomes: SSRI adverse effect severity and depression remission at 6 months.

Main Results:

  • No significant differences were observed in depression symptom improvement (PROMIS T scores) at 3 months between the genotype-guided and usual care groups.
  • Adverse effect burden and Patient Health Questionnaire-8 (PHQ-8) score changes at 3 months also showed no significant group differences.
  • A significantly higher depression remission rate (PROMIS T-score ≤16) was observed in the genotype-guided group compared to the usual care group at 6 months (48.3% vs. 39.4%, P=.02).

Conclusions:

  • Genotype-guided SSRI prescribing did not accelerate depression symptom control at 3 months but was linked to improved remission rates at 6 months.
  • These findings suggest a potential longer-term clinical benefit of pharmacogenetic guidance in managing depressive symptoms.
  • Further research is warranted to investigate the durability and long-term impact of genotype-guided prescribing on depression management.